[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-339271-105":59,"doc-detail-339271-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","ph-responsive-targeted-nanoparticles-release-erk-inhibitor-in-the-hypoxic-zone-and-sensitize-free-gemcitabine-in-mutant-k-ras-addicted-pancreatic-cancer-cells-and-mouse-model","pH-responsive targeted nanoparticles release ERK-inhibitor in the hypoxic zone and sensitize free gemcitabine in mutant K-Ras-addicted pancreatic cancer cells and mouse model","","Therapeutic options for pancreatic ductal adenocarcinoma (PDAC) are limited, with gemcitabine (GEM) remaining first-line despite suboptimal effects. GEM constraints stem from poor bioavailability and chemoresistance driven by mutant K-RAS/AKT/ERK signaling, which promotes desmoplastic barriers and creates a hypoxic microenvironment. The study develops pH-responsive ERK-inhibitor nanoparticles encapsulating SCH772984 and decorated with iRGD to target PDAC. The nanocarrier releases ERKi under hypoxic, low-pH conditions and shows synergistic tumor growth inhibition in vitro and in vivo with free GEM. Mechanistically, ERKi reduces desmoplasia by impairing desmoplastic regulatory factor production, prolonging survival in a genetically engineered KPC mouse model.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/ph-responsive-targeted-nanoparticles-release-erk-inhibitor-in-the-hypoxic-zone-and-sensitize-free-gemcitabine-in-mutant-k-ras-addicted-pancreatic-cancer-cells-and-mouse-model/339271/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/ph-responsive-targeted-nanoparticles-release-erk-inhibitor-in-the-hypoxic-zone-and-sensitize-free-gemcitabine-in-mutant-k-ras-addicted-pancreatic-cancer-cells-and-mouse-model/339271.png","ImageObject",300,407,{"name":92,"@type":93},"Emma Wilson","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",13,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What problem does the study address in PDAC treatment?","Question",{"text":113,"@type":114},"The study targets limited therapeutic efficacy of gemcitabine due to poor bioavailability and chemoresistance associated with mutant K-RAS/AKT/ERK signaling, desmoplastic barriers, and a hypoxic microenvironment.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"What nanoparticle platform is developed in this work?",{"text":118,"@type":114},"It uses pH-responsive nanoparticles that encapsulate the ERK inhibitor SCH772984 and are surface-functionalized with the tumor-penetrating peptide iRGD to improve PDAC targeting and release under hypoxic/low-pH conditions.",{"name":120,"@type":111,"acceptedAnswer":121},"How does the combination approach affect outcomes in vitro and in vivo?",{"text":122,"@type":114},"The combination of free GEM with nanoencapsulated ERKi produces significant synergistic treatment outcomes in vitro and enhanced GEM effects in PDAC growth inhibition, including prolonged survival in the KPC mouse model.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},339271,1790334479,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":26,"preview_page_count":19,"preview_urls":146},3848291630094,"https://eur-avatar.wpscdn.com/davatar_085a072bc5b1113ac321206ff7593b45","PLOS ONE  \nOPEN ACCESS  \nCitation: Dutta D, Ray P, De A, Ghosh A, Hazra RS, Ghosh P, et al. (2024) pH-responsive targeted nanoparticles release ERK-inhibitor in the hypoxic zone and sensitize free gemcitabine in mutant KRas-addicted pancreatic cancer cells and mouse model. PLoS ONE 19(4): e0297749 . [https://doi](https://doi). org/10 .1371/journal.pone.0297749  \nEditor: Pankaj K. Singh, OUHSC: The University of Oklahoma Health Sciences Center, UNITED STATES  \nReceived: September 24, 2023  \nAccepted: January 12, 2024  \nPublished: April 30, 2024  \nCopyright: This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.  \nData Availability Statement: The minimal anonymized data set necessary to replicate our study findings in a stable, public repository can be accessed via the following DOI: 10.7910/DVN/ FXKETO.  \nFunding: This study was funded by the VA Merit Medical Systems (Grant No. 5I01BX001002-11) awarded to SB, by the VA Merit Funding System (Grant No. 5I01BX004497-04) awarded to SKB, by  \nRESEARCH ARTICLE  \npH-responsive targeted nanoparticles release ERK-inhibitor in the hypoxic zone and sensitize free gemcitabine in mutant K-Rasaddicted pancreatic cancer cells and mouse model  \nDebasmita Dutta1¤a, Priyanka Ray1, Archana De2, Arnab Ghosh2,3¤b, Raj Shankar Hazra1, Pratyusha Ghosh1,2, Snigdha Banerjee2,3 *, Francisco J. Diaz4, Sunil P. Upadhyay2,3, Mohiuddin Quadir1 *, Sushanta K. Banerjee2,3 *  \n1 Department of Coatings and Polymeric Materials, North Dakota State University, Fargo, ND, United States of America, 2 Cancer Research Unit, VA Medical Center, Kansas City, MO, United States of America,  \n3 Department of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, KS, United States of America, 4 Department of Biostatistics & Data Science, University of Kansas Medical Center, Kansas City, KS, United States of America  \n¤a Current address: Dept. of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, United States of America  \n¤b Current address: Department of Zoology, Rajiv Gandhi University, Papum Pare, AP, India  \n* [Snigdha.banerjee@va.gov](Snigdha.banerjee@va.gov) (SB); [sbanerjee2@kumc.edu](sbanerjee2@kumc.edu), [cancerresearchunit@icloud.com](cancerresearchunit@icloud.com) (SKB);  \n[Mohiuddin.quadir@ndsu.edu](Mohiuddin.quadir@ndsu.edu) (MQ)  \nAbstract  \nTherapeutic options for managing Pancreatic ductal adenocarcinoma (PDAC), one of the deadliest types of aggressive malignancies, are limited and disappointing. Therefore, despite suboptimal clinical effects, gemcitabine (GEM) remains the first-line chemotherapeutic drug in the clinic for PDAC treatment. The therapeutic limitations of GEM are primarily due to poor bioavailability and the development of chemoresistance resulting from the addiction of mutant-K-RAS/AKT/ERK signaling-mediated desmoplastic barriers with a hypoxic microenvironment. Several new therapeutic approaches, including nanoparticle-assisted drug delivery, are being investigated by us and others. This study used pH-responsive nanoparticles encapsulated ERK inhibitor (SCH772984) and surface functionalized with tumor-penetrating peptide, iRGD, to target PDAC tumors. We used a small molecule, SCH772984, to target ERK1 and ERK2 in PDAC and other cancer cells. This nanocarrier efficiently released ERKi in hypoxic and low-pH environments. We also found that the freeGEM, which is functionally weak when combined with nanoencapsulated ERKi, led to significant synergistic treatment outcomes in vitro and in vivo. In particular, the combination approaches significantly enhanced the GEM effect in PDAC growth inhibition and prolonged survival of the animals in a genetically engineered KPC (LSL-KrasG12D/+/LSLTrp53R172H/+/Pdx-1-Cre) pancreatic cancer mous","cbCaim8P8oaBwga6","https://ap.wps.com/l/cbCaim8P8oaBwga6","pdf",4442856,24,"English","# Abstract\n## Introduction","[{\"question\":\"What problem does the study address in PDAC treatment?\",\"answer\":\"The study targets limited therapeutic efficacy of gemcitabine due to poor bioavailability and chemoresistance associated with mutant K-RAS/AKT/ERK signaling, desmoplastic barriers, and a hypoxic microenvironment.\"},{\"question\":\"What nanoparticle platform is developed in this work?\",\"answer\":\"It uses pH-responsive nanoparticles that encapsulate the ERK inhibitor SCH772984 and are surface-functionalized with the tumor-penetrating peptide iRGD to improve PDAC targeting and release under hypoxic/low-pH conditions.\"},{\"question\":\"How does the combination approach affect outcomes in vitro and in vivo?\",\"answer\":\"The combination of free GEM with nanoencapsulated ERKi produces significant synergistic treatment outcomes in vitro and enhanced GEM effects in PDAC growth inhibition, including prolonged survival in the KPC mouse model.\"}]","pH-responsive targeted nanoparticles release ERK-inhibitor in the hypoxic zone and sensitize free gemcitabine in mutant K-Ras-addicted pancreatic cancer cells and mouse model | PDF",1790029097,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/56611e1f4ea00cfec42641bd8234ce39.webp",983,1272,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/70f1588256c221f113d281d060e89004.webp",982,1270,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7a00356ad1b314a3fa285ebb21efb561.webp",981,1269,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0ddd92ef42158a8f34e45b66f50a35bc.webp",980,1268]